NCT06706713View on ClinicalTrials.gov

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Non-Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Interventions
DRUG

BEBT-109 Capsule

Take orally before breakfast and dinner each day, with a minimum interval of 9 hours between doses, 120mg each time, twice a day,and 28 days as a treatment cycle.

Trial Locations (2)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

510080

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

Sponsors

Lead Sponsor

BeBetter Med Inc
All Listed Sponsors
lead

BeBetter Med Inc

INDUSTRY